X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined company will focus on the development of AEZS-130 (macimorelin), a ghrelin receptor agonist and a small molecule that stimulates the secretion of growth hormone from the pituitary gland.
Lead Product(s): Macimorelin
Therapeutic Area: Neurology Product Name: AEZS-130
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aeterna Zentaris
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 14, 2023
Details:
Avenanthramides provide relief from a host of skin conditions, such as eczema, allergic rash, chicken pox and insect bites. Ceapro is the only commercial manufacturer of commercially available avenanthramides extracted and purified from oats.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
Avenanthramides (AVA) are di-phenolic compounds found only in oats and are of interest due to suggested bioactivities, including antioxidant and anti-inflammatory effects in vitro and in vivo.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
Data demonstrated that PGX-processed yeast beta glucan (PGX-YBG) is respirable and able to safely and reliably reprogram macrophages in the lungs in pre-clinical mouse models.
Lead Product(s): PGX-processed Yeast Beta Glucan
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PGX-YBG
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: McMaster University
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
Oat-based bioactives BG and AV exhibited potential to improve regenerative wound healing, reduce inflammation, promote angiogenesis, and reduce scar formation.
Lead Product(s): Oat Beta Glucan
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Angiogenesis Foundation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
Avenanthramides provide relief from a host of skin conditions, such as eczema, allergic rash, chicken pox and insect bites. Ceapro is the only commercial manufacturer of commercially available avenanthramides extracted and purified from oats.
Lead Product(s): Avenanthramide
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
Details:
To advance this promising technology into clinical trials, the aim of the project is to optimize the delivery of PGX-YBG to lung and validate its performance for reducing lung fibrosis, both alone and loaded with an anti-inflammatory drug currently used for COVID-19 therapy.
Lead Product(s): PGX-YBG
Therapeutic Area: Infections and Infectious Diseases Product Name: PGX-YBG
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: McMaster University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 11, 2022
Details:
Under the agreement, Symrise is guaranteed to purchase minimum annual volumes of Ceapro’s high value active ingredients. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.
Lead Product(s): Oat Beta Glucan,Avenanthramides
Therapeutic Area: Dermatology Product Name: Juvente
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Symrise
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 10, 2022
Details:
The effect of oat beta glucan on the study primary endpoint is change in LDL-C, and some positive findings observed with different parameters, there were dosage-related responses in weight and body-mass index at 12 weeks but they also did not reach statistical significance.
Lead Product(s): Beta Glucan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2021
Details:
Under the collaboration, pre-clinical studies using methods developed by the Angiogenesis Foundation will be conducted to characterize the in vivo bioactivity of Ceapro’s oat-derived bioactive products, beta glucan and avenanthramides.
Lead Product(s): Beta Glucan
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Angiogenesis Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 23, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
